SSSanjeeb Kumar Sahoo

Sanjeeb Kumar Sahoo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sanjeeb Kumar Sahoo has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Fahima Dilnawaz

    Laboratory of Nanomedicine, Institute of life sciences, Bhubaneswar-751023, Odisha, India

    11 shared publications
  • Pratikshya Sa

    Institute of Life Sciences, Nalco Square, Bhubaneswar 751023, Odisha, India

    7 shared publications
  • Priya Singh

    Institute of Life Sciences, Nalco square, Chandrasekharpur, Bhubaneswar, Odisha 751 023, India; Regional Centre for Biotechnology, Faridabad-Gurgaon Expressway, Faridabad, Haryana 121 001, India

    7 shared publications
  • Manasi Das

    Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, Odisha, India

    6 shared publications
  • Priyanka Mohapatra

    Institute of Life Sciences, Nalco Square, Bhubaneswar 751023, Odisha, India

    5 shared publications
  • Abhalaxmi Singh

    University of Illinois College of Medicine 2 Department of Pharmacology and Regenerative Medicine Chicago, IL, USA

    4 shared publications

Latest Publications

  • Comprehensive insight into nimbolide response against breast cancer treatment: present evidence, emerging strategy and future direction

    by Ayana Sarangi, Ananya Kashyap, Soumya Swarupa Panda, Sonali Sahoo, Sanjeeb Kumar Sahoo

    Breast cancer(BC) is a predominant malignancy, widely spread among women globally and has poor prognosis & clinical outcomes Conventional therapeutic approaches like surgery, chemotherapy and radiation therapy become insignificant due to the development of resistant clones, resilience in stemness, leads to metastasis and further relapse. Specifically, eradication of BC metastasis is challenging due to its intrinsic property of tumour cell plasticity, self-renewal ability and resistant to therapeutic agents. Therefore, systemic and targeted therapeutic approach becomes the primary focus in treatment regimen. Nimbolide a phytochemical derived from Azadirachta indica have demonstrated its potency as an antiproliferative, antimetastatic, anti-inflammatory and proapoptotic agent against a broad spectrum of different BC cell lines. Along with that, its antitumour activity has been validated by integrating its molecular mechanism emphasising different in-vitro/in-vivo studies on BC models. In this review, we provide a comprehensive analysis of nimbolide as an intriguing therapeutic phytochemical marker for BC, with main emphasis on the in vitro and in vivo studies and on the underlying molecular mechanisms. In addition to revealing the novel insights into the process of development of phytochemical on potent anticancer agents, this review seeks to come up with a scientific justification by focusing on current breakthroughs for the use of nimbolide in BC treatment with integration to nanotechnology.

  • 1,2‐Sulfonylative‐Arylation of Acrylamides via Strain‐Release‐/Aromaticity‐Driven Radical Generation and SO 2 ‐Capture under Photoredox Catalysis to Access S(VI)‐Oxindoles

    by Abhaykumar Vishwakarma, Tonish Kumar Sahu, Shanti Gopal Patra, Chhanda Paul, Somalisa Behera, Sanjeeb Sahoo, Tabrez Khan

    γ‐Keto sulfones, despite being a medicinally relevant building block, have never been integrated with the bioactive oxindole scaffold present in several alkaloid natural products. On the other hand, strategies involving SO 2 capture in organic molecules to access value‐added products are gaining momentum. Therefore, a strategy en route to γ‐keto alkylsulfonylated oxindoles bearing a β ‐all‐carbon quaternary center is disclosed. Toward this goal, the bisfunctionalization of N‐(hetero)arylacrylamides has been realized via the strain‐release driven ring‐scission of strained 3°‐cyclopropanols in the presence of DABSO under visible‐light photoredox catalysis to access a library of γ‐keto alkylsulfonylated oxindoles. Also, the aromaticity‐driven bond‐scission in pro‐aromatics like 4‐alkyl‐1,4‐DHPs in the presence of Na 2 S 2 O 5 under visible‐light photoredox catalysis has been exploited to trigger the alkylsulfonylative‐arylation of N‐(hetero)arylacrylamides to access a library of alkylsulfonylated oxindoles featuring a β‐all‐carbon quaternary center. Broad substrate scope is demonstrated, and the mechanistic probing studies have been complemented with DFT calculations. Also, moderate to potent cytotoxic activity is observed against the tested triple‐negative breast cancer cell lines for some of the synthesized sulfonylated oxindole derivatives. Further, evaluation of the mechanism of cell death for the most potent oxindole analog revealed that it induces apoptosis in a concentration‐dependent manner.


  • Enhancement of the Antitumor Efficacy of Docetaxel Using αvβ3 Integrin and CD44 Dual Receptor-Targeted Carbon Dot-Based Nanodelivery in Breast Cancer

    by Pradip Jana, Pratikshya Sa, Kentaro Sakai, Sanjeeb Kumar Sahoo, Harishkumar Madhyastha, Abhimanyu Dev

    Breast cancer is one of the most common forms of cancer, and an alternate treatment strategy for breast cancer is of utmost importance, as conventional therapy brings severe side effects. Here, we have developed a hyaluronic acid (HA) and cyclic arginine-glycine-aspartic acid peptide (cRGD)-conjugated docetaxel (DTX)-loaded nitrogen-doped carbon dot (CDU)-targeted delivery system for breast cancer. The developed dual-ligand-conjugated system (cRGD-HA-CDU@DTX) has exhibited a size below 100 nm, a high ζ potential (-24.3 mV), good biocompatibility, and good hydrophilicity. The cRGD-HA-CDU@DTX system has demonstrated a high drug loading efficiency (77.53%) and shown an acidic pH (pH 5.0)-dependent drug release of 90% after 48 h. According to the in vitro cytotoxicity study in the Michigan Cancer Foundation-7 (MCF-7) cancer cell line, the IC50 value for the cRGD-HA-CDU@DTX system is found to be 3.167 μM, while for DTX, it is found to be 4.068 μM, indicating better cytotoxicity of the dual-ligand-conjugated system. Cellular uptake study exhibited the excellent internalization of the dual-ligand-conjugated system and a higher reactive oxygen species (ROS) production in cRGD-HA-CDU@DTX as compared to native DTX is seen. Flow cytometry analysis in MCF-7 cells demonstrated an almost 3-fold increased apoptotic cell death for the cRGD-HA-CDU@DTX group compared to DTX alone. Additionally, cell cycle analysis revealed 15% G2/M arrest in the cRGD-HA-CDU@DTX-treated cells, whereas only 3.6% G2/M arrest was noted for DTX. Further, the cRGD-HA-CDU@DTX system exhibited a significant upregulation and downregulation of proapoptotic and antiapoptotic genes, respectively. Finally, in vivo antitumor study displayed a 64.12% tumor growth reduction in the cRGD-HA-CDU@DTX-treated group, while DTX exhibited only a 39.98% tumor growth reduction. Thus, the overall study demonstrated that the cRGD-HA-CDU@DTX system can serve as a potential targeted nanodrug delivery system to reduce side effects and to improve therapeutic efficacy in breast cancer.


  • Phytonanomedicine as a therapeutic regulator of the tumor microenvironment for inhibiting cancer metastasis

    by Sonali Sahoo, Sanjeeb Kumar Sahoo

    TWEETABLE ABSTRACT “The development of phytonanomedicine-based approach seems to be a very promising candidate for modulating protumorigenic tumor microenvironment to suppress cancer metastasis.”


  • Piperlongumine and its derivatives against cancer: A recent update and future prospective

    by Shasank S. Swain, Sanjeeb K. Sahoo

    Piperlongumine, or piplartine (PL), is a bioactive alkaloid isolated from Piper longum L. and a potent phytoconstituent in Indian Ayurveda and traditional Chinese medicine with a lot of therapeutic benefits. Apart from all of its biological activities, it demonstrates multimodal anticancer activity by targeting various cancer‐associated pathways and being less toxic to normal cells. According to their structure–activity relationship (SAR), the trimethylphenyl ring (cinnamoyl core) and 5,6‐dihydropyridin‐2‐(1H)‐one (piperdine core) are responsible for the potent anticancer activity. However, it has poor intrinsic properties (low aqueous solubility, poor bioavailability, etc.). As a result, pharmaceutical researchers have been trying to optimise or modify the structure of PL to improve the drug‐likeness profiles. The present review selected 26 eligible research articles on PL derivatives published between 2012 and 2023, followed by the preferred reporting items for systematic reviews and meta‐analyses (PRISMA) format. We have thoroughly summarised the anticancer potency, mode of action, SAR and drug chemistry of the proposed PL‐derivatives against different cancer cells. Overall, SAR analyses with respect to anticancer potency and drug‐ability revealed that substitution of methoxy to hydroxyl, attachment of ligustrazine and 4‐hydroxycoumarin heterocyclic rings in place of phenyl rings, and attachment of heterocyclic rings like indole at the C7‐C8 olefin position in native PL can help to improve anticancer activity, aqueous solubility, cell permeability, and bioavailability, making them potential leads. Hopefully, the large‐scale collection and critical drug‐chemistry analyses will be helpful to pharmaceutical and academic researchers in developing potential, less‐toxic and cost‐effective PL‐derivatives that can be used against different cancers.


  • Piperlongumine based nanomedicine impairs glycolytic metabolism in triple negative breast cancer stem cells through modulation of GAPDH & FBP1

    by Priya Singh, Kaushik Sen, Pratikshya Sa, Auromira Khuntia, Sunil K. Raghav, Rajeeb K. Swain, Sanjeeb Kumar Sahoo


  • Open Access

    Essential oils and their nanoformulations for breast cancer therapy

    by Muhammed Ashiq Thalappil, Priya Singh, Alessandra Carcereri de Prati, Sanjeeb Kumar Sahoo, Sofia Mariotto, Elena Butturini

    Breast Cancer (BC) is the most prevalent type of cancer in the world. Current treatments include surgery, radiation, and chemotherapy but often are associated with high toxicity to normal tissues, chemoresistance, and relapse. Thus, developing novel therapies which could combat these limitations is essential for effective treatment. In this context, phytochemicals are increasingly getting popular due to their safety profile, ability to efficiently target tumors, and circumvent limitations of existing treatments. Essential Oils (EOs) are mixtures of various phytochemicals which have shown potential anticancer activity in preclinical BC models. However, their clinical translation is limited by factors such as high volatility, low stability, and poor solubility. Nanotechnology has facilitated their encapsulation in a variety of nanostructures and proven to overcome these limitations. In this review, we have efficiently summarized the current knowledge on the anticancer effect of EOs and constituents in both in in vitro and in in vivo BC models. Further, we also provide a descriptive account on the potential of nanotechnology in enhancing the anti‐BC activity of EOs and their constituents. The papers discussed in this review were selected using the keywords “antiproliferative Essential Oils in breast cancer,” “anticancer activity of Essential Oil in breast cancer,” and “cytotoxicity of Essential Oils in breast cancer” performed in PubMed and ScienceDirect databases.


  • Open Access

    Nimbolide-based nanomedicine inhibits breast cancer stem-like cells by epigenetic reprogramming of DNMTs-SFRP1-Wnt/β-catenin signaling axis

    by Priyanka Mohapatra, Swati Madhulika, Somalisa Behera, Priya Singh, Pratikshya Sa, Punit Prasad, Rajeeb Kumar Swain, Sanjeeb Kumar Sahoo